NRx Pharmaceuticals to Announce Q1 2024 Financials on May 14, 2024

RADNOR, Pa., May 7, 2024 — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, has announced that it will release its first quarter 2024 financial results on Tuesday, May 14, 2024, after the market closes. The press release will be accessible on the company's website. On the same day, at 4:30pm ET, NRx Pharmaceuticals will host a conference call to discuss the financial results and provide a corporate update.

A live webcast of the conference call will be available on the company's website. For those unable to join the webcast, the conference call can be accessed by dialing domestically at +1-800-717-1738 or internationally at +1-646-307-1865.

NRx Pharmaceuticals is dedicated to developing therapeutics based on its NMDA platform to treat central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD. One of its primary developments is NRX-101, recognized as an FDA-designated investigational Breakthrough Therapy. NRX-101 is being developed for the treatment of suicidal treatment-resistant bipolar depression and chronic pain. Additionally, NRx has collaborations with Alvogen and Lotus to advance and market NRX-101 for treating suicidal bipolar depression. This therapy also has the potential to be a non-opioid treatment for chronic pain and a remedy for complicated urinary tract infections (UTIs).

In recent developments, NRx Pharmaceuticals has outlined plans to submit a New Drug Application for HTX-100, an intravenous form of ketamine, through its subsidiary Hope Therapeutics. This application is based on robust clinical trial results conducted in collaboration with the US National Institutes of Health and new data from French health authorities, obtained via a data sharing agreement. The US FDA has awarded Fast Track Designation for the development of ketamine (NRX-100) as part of a protocol to treat patients experiencing acute suicidality.

Hope Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, focuses on developing and marketing an FDA-approved form of intravenous ketamine for treating acute suicidality and depression. They aim to create a digital therapeutic platform to enhance and maintain the clinical benefits of NMDA-targeted drug therapies.

NRx Pharmaceuticals continues to drive forward with innovative treatments addressing severe central nervous system disorders, offering hope to patients and advancing medical science in areas of critical need.